Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis (Col-Strepto B)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01719510
First received: October 30, 2012
Last updated: July 25, 2014
Last verified: July 2014

October 30, 2012
July 25, 2014
November 2012
November 2014   (final data collection date for primary outcome measure)
Detection of the hyper-virulent ST17 clone of Group B Strep [ Time Frame: at 60 days post delivery ] [ Designated as safety issue: No ]
Detection of the hyper-virulent ST17 clone of Group B Strep (GBS) in the prevention of neonatal GBS meningitis. The main objective is to demonstrate that the hypervirulent ST17 GBS clone colonizing the mother and postpartum acquired colonizes and persists at 60 days post delivery in the gut of new born significantly more than non-ST17 GBS strains.
Same as current
Complete list of historical versions of study NCT01719510 on ClinicalTrials.gov Archive Site
  • Digestive colonization [ Time Frame: at day 21 ] [ Designated as safety issue: No ]
    Digestive colonization of ST17 clone of Group B Strep in the newborns
  • Milk colonization [ Time Frame: at day 21 and day 60 ] [ Designated as safety issue: No ]
    Colonization of milk by ST17 clone of Group B Strep
  • Vaginal colonization [ Time Frame: at day 21 and day 60 ] [ Designated as safety issue: No ]
    Vaginal colonization by ST17 clone of Group B Strep
  • Late neonatal infections [ Time Frame: between 3 weeks and 60 days ] [ Designated as safety issue: No ]
    Late neonatal infections will be observed between 3 weeks and 60 days
Same as current
Not Provided
Not Provided
 
Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis
Study of the Digestive Colonization of the Newborn Children by the Streptococcus of the Group B

The main objective of this study : Demonstrate that GBS (group B streptococci) "ST-17" colonize and persist to 60 days twice in the digestive tract of newborns that strains of GBS non-ST-17.

Secondary objectives:Determine:

  • The frequency of colonization with GBS ST-17 and GBS non-ST-17 of at risk pregnant women.
  • The frequency of colonization of neonates by GBS ST-17 at birth.
  • The preferential site of colonization in the mother (rectum, vagina, breast milk).
  • The kinetics of colonization after birth in the newborn.
  • The sensitivity and specificity of different GBS detection methods (conventional phenotypic versus molecular) in the different types of samples from the mother and the newborn.

Women tested positive for GBS during systematic vaginal screening at 35-37 weeks, will be proposed to participate to the study and will be included after reading the information letter and signature the consent form.

INCLUSION (D0 at time of delivery)

In the labor ward, two women's groups 1 and 2:

Group 1 = Women tested positive for GBS pre-selected and included in the protocol (see pre-inclusion) Group 2 = Women without antenatal vaginal screening and at risk of neonatal infection.

For both groups, at time of delivery:

At the beginning of the labour performed vaginal swabs (PV0):

  • one swab for GBS detection by real-time PCR using the Cepheid technique conducted in the labor ward by the midwife.
  • the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.

For all women included (Group 1 and Group 2 women with a positive GBS vaginal sample) will be achieved in the delivery room:

  1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.
  2. A sampling of umbilical cord blood. Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home. Samples will be sent to the bacteriology laboratory and analyzed by classical bacteriological method (culture) and / or real-time PCR.

For mothers, the collection of 3-5 ml of milk when breastfeeding.

Monitoring schedule:

Day 21 and day 60 post delivery:

the following samples for search of GBS for will be performed to gather the primary endpoint:

For the mother:

  • Vaginal sample.
  • Collection of 3-5 ml of breast milk when breastfeeding

For the newborn:

  • Sample collection of feces
  • Swab of buccal cavity

Processing bacteriological samples:

All samples will be subjected to bacteriological analysis and DNA extraction for detection of GBS. GBS isolated will be identified and stored at - 80 ° C in a declared biological collection. DNA extracts will also stored at -20 ° C in a declared biological collection. All samples for microbiological analysis will be stored at - 80 ° C.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Women at Risk of Neonatal Infections Colonize With GBS (Group B Streptococci).
Other: Samples

At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.

For both groups:

  • one swab for GBS detection by real-time PCR
  • the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.

For all women included will be achieved in the delivery room:

  1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.
  2. A sampling of umbilical cord blood.

Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.

For mothers, the collection of 3-5 ml of milk when breastfeeding.

Positive Group B Streptococcus vaginal sample

At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.

For all women included will be achieved in the delivery room:

a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.

For mothers, the collection of milk when breastfeeding.

Intervention: Other: Samples
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
900
April 2015
November 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient having a positive vaginal swab for GBS at the end of pregnancy (PCR +).
  • Patient aged over 18 years
  • Patient who received information and agreeing to sign informed consent
  • Patient affiliated or beneficiary of an insurance

Exclusion Criteria:

- Patient does not speak and does not understand French

Female
18 Years and older
No
Contact: Claire POYART, MD, PhD +33158411560 claire.poyart@cch.aphp.fr
Contact: Laurence Lecomte, PhD +33 1 71 19 64 94 laurence.lecomte@nck.aphp.fr
France
 
NCT01719510
P111008
No
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Claire POYART, MD, PhD Cochin Hospital
Assistance Publique - Hôpitaux de Paris
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP